Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Psychiatry
Published in: BMC Psychiatry 1/2018

Open Access 01-12-2018 | Research article

A pilot feasibility randomised controlled trial of an adjunct brief social network intervention in opiate substitution treatment services

Authors: Ed Day, Alex Copello, Jennifer L. Seddon, Marilyn Christie, Deborah Bamber, Charlotte Powell, Carmel Bennett, Shabana Akhtar, Sanju George, Andrew Ball, Emma Frew, Ilias Goranitis, Nick Freemantle

Published in: BMC Psychiatry | Issue 1/2018

Login to get access

Abstract

Background

Approximately 3% of people receiving opioid substitution therapy (OST) in the UK manage to achieve abstinence from prescribed and illicit drugs within three years of commencing treatment. Involvement of families and wider social networks in supporting psychological treatment may be an effective strategy in facilitating recovery, and this pilot study aimed to evaluate the impact of a social network-focused intervention for patients receiving OST.

Methods

A two-site, open feasibility trial randomised patients receiving OST for at least 12 months but still reporting illicit opiate use in the past 28 days to one of three treatments: 1) treatment as usual (TAU), 2) Brief Social Behaviour and Network Therapy (B-SBNT) + TAU, or 3) Personal Goal Setting (PGS) + TAU. The two active interventions consisted of 4 sessions. There were 3 aims: 1) test the feasibility of recruiting OST patients to a trial of B-SBNT, and following them up over 12 months; 2) test the feasibility of training clinicians to deliver B-SBNT; 3) test whether B-SBNT reduces heroin use 3 and 12 months after treatment, and to explore potential mediating factors. The primary outcome for aim 3 was number of days of heroin use in the past month, and a range of secondary outcome measures were specified in advance (level of drug dependence, mental health, social satisfaction, therapist rapport, treatment satisfaction, social network size and support).

Results

A total of 83 participants were randomised, and 70 (84%) were followed-up at 12 months. Fidelity analysis of showed that B-SBNT sessions were clearly distinguishable from PGS and TAU sessions, suggesting it was possible to train clinical staff to an adequate level of competence.
No significant differences were found between the 3 intervention arms in the primary or secondary outcome measures. Attendance at psychosocial treatment intervention sessions was low across all three arms (44% overall).

Conclusions

Patients receiving OST can be recruited into a trial of a social network-based intervention, but poor attendance at treatment sessions makes it uncertain whether an adequate dose of treatment was delivered. In order to achieve the benefits of psychosocial interventions, further work is needed to overcome poor engagement.

Trial registration

ISRCTN Trial Registration Number: ISRCTN22608399.
Date of registration: 27/04/2012. Date of first randomisation: 14/08/2012.
Appendix
Available only for authorised users
Literature
1.
Best D, George S, Day E. The development of the drug treatment system in England. In: Day E, editor. Clinical topics in addiction. London: RCPsych; 2007. p. 14–28.
2.
HM Government. Drug strategy 2010. Reducing demand, restricting supply, building recovery: supporting people to live a drug free life. London: Home Office; 2010.
3.
McKeganey N, Bloor M, Robertson M, Neale J, MacDougall J. Abstinence and drug abuse treatment: results from the drug outcome research in Scotland study. Drugs Educ Prev Policy. 2006;13(6):537–50.CrossRef
4.
Day E, Mitcheson L. Psychosocial interventions in OST services: does the evidence provide a case for optimism or nihilism? Addiction. 2017;113(8):1329–36.CrossRef
5.
Drummond DC, Kouimtsidis C, Reynolds M, Russell I, Godfrey C, McCusker M, Coulton S, Parrott S, Davis P, Tarrier N et al: The effectiveness and cost effectiveness of cognitive behaviour therapy for opiate misusers in methadone maintenance treatment: a multicentre randomised controlled trial (UKCBTMM). Final report to the Department of Health Research and Development Directorate. In. London: Department of Health; 2004.
6.
Best D, Hernando R, Gossop M, Sidwell C, Strang J. Getting by with a little help from your friends, the impact of peer networks on criminality in a cohort of treatment-seeking drug users. Addict Behav. 2003;28:597–603.CrossRefPubMed
7.
Gogineni A, Stein M, Friedmann PD. Social relationships and intravenous drug use among methadone maintenance patients. Drug Alcohol Depend. 2001;64:47–53.CrossRefPubMed
8.
Latkin C, Mandell W, Oziemkowska M, Celentano D, Vlahov D, Ensminger M, Knowlton A. Using social network analysis to study patterns of drug use among urban drug users at high risk for HIV/AIDS. Drug Alcohol Depend. 1995;38(1):1–9.CrossRefPubMed
9.
Schroeder JR, Latkin CA, Hoover DR, Curry AD, Knowlton AR, Celentano DD. Illicit drug use in one’s social network and in one's neighbourhood predicts individual heroin and cocaine use. Ann Epidemiol. 2001;11:389–94.CrossRefPubMed
10.
Cohen S, Lichtenstein E. Partner Behaviours that support quitting smoking. J Consult Clin Psychol. 1990;58(3):304–9.CrossRefPubMed
11.
Goehl L, Nunes E, Quitkin F, Hilton I. Social networks and methadone treatment outcome: the costs and benefits of social ties. Am J Drug Alcohol Abuse. 1993;19(3):251–62.CrossRefPubMed
12.
Havassy BE, Wasserman DA, Hall SM. Social relationships and abstinence from cocaine in an American treatment sample. Addiction. 1995;90:699–710.CrossRefPubMed
13.
Wasserman DA, Stewart AL, Delucchi KL. Social support and abstinence from opiates and cocaine during opioid maintenance treatment. Drug Alcohol Depend. 2001;65:65–75.CrossRefPubMed
14.
Zywiak WH, Neighbors CJ, Martin RA, Johnson JE, Eaton CA, Rohsenow DJ. The important people drug and alcohol interview: psychometric properties, predictive validity, and implications for treatment. J Subst Abus Treat. 2009;36:321–30.CrossRef
15.
Centre for Social Justice. Green paper on criminal justice and addiction. London: The Centre for Social Justice; 2010.
16.
National Treatment Agency for Substance Misuse. NTA policy on involvement of users and family members. London: NTA; 2008.
17.
National Treatment Agency for Substance Misuse. NTA business plan 2010–11. London: NTA; 2010.
18.
The Betty Ford Institute Consensus Panel. What is recovery? A working definition from the Betty ford institute. J Subst Abus Treat. 2007;33:221–8.CrossRef
19.
Goranitis I, Coast J, Day E, Copello A, Freemantle N, Frew E. Maximizing health or sufficient capability in economic evaluation? A methodological experiment of treatment for drug addiction. Med Decis Mak. 2017;37(5):498–511.CrossRef
20.
Goranitis I, Coast J, Day E, Copello A, Freemantle N, Seddon J, Bennett C, Frew E. Measuring health and broader well-being benefits in the context of opiate dependence: the psychometric performance of the ICECAP-A and the EQ-5D-5L. Value Health. 2016;19:820–8.CrossRefPubMed
21.
Best D, Day E, Morgan B, Oza T, Copello A, Gossop M. What treatment means in practice: an analysis of the delivery of evidence-based structured interventions in criminal justice drug treatment services in Birmingham, England. Addict Res Theory. 2009;17(6):678–87.CrossRef
22.
Copello A, Orford J, Hodgson R, Tober G, Barrett C. Social behaviour and network therapy - basic principles and early experiences. Addict Behav. 2002;27(3):345–66.CrossRefPubMed
23.
UKATT Research Team. Effectiveness of treatment for alcohol problems: findings of the randomised UK alcohol treatment trial (UKATT). BMJ. 2005;331(7516):541–4.CrossRef
24.
UKATT Research Team. Cost effectiveness of treatment for alcohol problems: findings of the randomised UK alcohol treatment trial (UKATT). BMJ. 2005;331(7516):544–8.CrossRef
25.
Copello A, Williamson E, Orford J, Day E. Implementing and evaluating social behaviour and network therapy in drug treatment practice in the UK: a feasibility study. Addict Behav. 2006;31(5):802–10.CrossRefPubMed
26.
Dale V, Coulton S, Godfrey C, Copello A, Hodgson R, Heather N, Orford J, Raistrick D, Slegg G, Tober G, et al. Exploring treatment attendance and its relationship to outcome in a randomized controlled trial of treatment for alcohol problems: secondary analysis of the UK alcohol treatment trial (UKATT). Alcohol Alcohol. 2011;46(5):592–9.CrossRefPubMed
27.
Dansereau DF, Simpson DD. A picture is worth a thousand words: the case for graphic representations. Prof Psychol. 2009;40(1):104–10.CrossRef
28.
Day E. Building bridges to positive social identities: the social network diagram and opiate substitution treatment. In: Buckingham SA, Best D, editors. Addiction, Behavioural change and social identity. Abingdon: Routledge; 2017.
29.
Day E, Best D, Bartholomew NG, Dansereau DF, Simpson DD. The BTEI care planning manual: mapping achievable goals. In: Routes to recovery. London: National Treatment Agency for Substance Misuse; 2008.
30.
Tober G, Clyne W, Finnegan O, Farrin A, Russell I, UKATT Research Team. Validation of a scale for rating the delivery of psycho-social treatments for alcohol dependence and misuse: the UKATT process rating scale (PRS). Alcohol Alcohol. 2008;43(6):675–82.CrossRefPubMed
31.
Marsden J, Farrell M, Bradbury C, Dale-Perera A, Eastwood B, Roxborough M, Taylor S. Development of the treatment outcomes profile. Addiction. 2008;103:1450–60.CrossRefPubMed
32.
Pocock SJ. Clinical trials: a practical approach. Chichester: John Wiley & Sons; 1983.
33.
Day E, Copello A, Seddon J, Christie M, Bamber D, Powell C, George S, Ball A, Frew E, Freemantle N. Pilot study of a social network intervention for heroin users in opiate substitution treatment: study protocol for a randomized controlled trial. Trials. 2013;14(1):264.CrossRefPubMedPubMedCentral
34.
Marsden J, Gossop M, Stewart D, Best D, Farrell M, Strang J. The Maudsley addiction profile: development and user manual. London: National Addiction Centre/Institute of Psychiatry; 1998.
35.
Raistrick D, Bradshaw J, Tober G, Weiner J, Allison J, Healey C. Development of the Leeds dependence questionnaire (LDQ): a questionnaire to measure alcohol and opiate dependence in the context of a treatment evaluation package. Addiction. 1994;89:563–72.CrossRefPubMed
36.
Evans C, Connell J, Barkham M, Margison F, McGrath G, Mellor-Clark J, Audin K. Towards a standardized brief outcome measure: psychometric properties and utility of the CORE-OM. Br J Psychiatry. 2002;180:51–60.CrossRefPubMed
37.
Raistrick D, Tober G, Heather N, Clark JA. Validation of the social satisfaction questionnaire for outcome evaluation in substance use disorders. Psychiatr Bull. 2007;31:333–6.CrossRef
38.
Heather N, Luce A, Peck D, Dunbar B, James I. Development of a treatment version of the readiness to change questionnaire. Addict Res. 1999;7(1):63–83.CrossRef
39.
Prochaska JO, DiClemente CC. Transtheoretical therapy: toward a more integrative model of change. Psychother Theory Res Pract Train. 1982;19(3):276–88.CrossRef
40.
Cohen S, Mermelstein R, Kamarck T, Hoberman HM. Measuring the functional components of social support. In: Sarason IG, Sarason BR, editors. Measuring the functional components of social support. London: Springer; 1985. p. 73–94.
41.
Joe GW, Broome KM, Rowan-Szal GA, Simpson DD. Measuring patient attributes and engagement in treatment. J Subst Abus Treat. 2002;22:183–96.CrossRef
42.
SAS Institute Inc. Chapter 6: introduction to mixed Modelling procedures. In: SAS/STAT 92 User’s guide (second edition). Cary: SAS Institute Inc.; 2009. p. 127–40.
43.
KO MG, Wong SP. Forming inferences about some intraclass correlation coefficients. Psychol Methods. 1996;1(1):30–46.CrossRef
44.
Schulz KF, Altman DG, Moher D, Group ftC. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332.CrossRefPubMedPubMedCentral
45.
National Collaborating Centre for Mental Health. Drug misuse: psychosocial interventions. London: British Psychological Society & The Royal College of Psychiatrists; 2008.
46.
Drummond C. Cuts to addiction services are a false economy. In: The bmj opinion, vol. 2017: BMJ; 2017.
47.
Mohammadi D. Addiction Services in England: in need of an intervention. Lancet Psychiatry. 2014;1:421–2.CrossRefPubMed
48.
AT ML, Starrels JL, Tai B, Gordon AJ, Brown R, Ghitza U, Gourevitch M, Stein J, Oros M, Horton T, et al. Can substance use disorders be managed using the chronic care model? Review and recommendations from a NIDA consensus group. Public Health Rev. 2013;35(2):8.CrossRef
49.
White WL. Recovery management and recovery-oriented systems of care: scientific rationale and promising practices. Northeast Addiction Technology Transfer Center: Pittsburgh; 2008.
50.
Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Fry-Smith A, Day E, Linzeris N, Roberts T, Burls A, et al. Methadone and Buprenorphine for the Management of Opioid Dependence: a systematic review and economic evaluation. Health Technol Assess. 2006;11(9):1–171.
51.
Ball JC, Ross A. The effectiveness of methadone maintenance treatment: patients, progress, services and outcomes. New York: Springer-Verlag; 1991.CrossRef
52.
Kraft MK, Rothbard AB, Hadley TR, AT ML, Asch DA. Are supplementary services provided during methadone maintenance really cost-effective? Am J Psychiatr. 1997;154(9):1214–9.CrossRefPubMed
53.
AT ML, Hagan TA, Levine M, Gould F, Meyers K, Bencivengo M, Durell J. Supplemental social services improve outcomes in public addiction treatment. Addiction. 1998;93(10):1489–99.CrossRef
54.
Amato L, Minozzi S, Davoli M, Vecchi S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Coch Database Syst Rev. 2011;10:CD004147.
55.
Weiss RD, Potter JS, Fiellin DA, Byrne M, Connery HS, Dickinson W, Gardin J, Griffin LM, Gourevitch MN, Haller DL, et al. Adjunctive counseling during brief and extended Buprenorphine-Naloxone treatment for prescription Opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry. 2011;68(12):1238–46.CrossRefPubMedPubMedCentral
56.
Otto MW, Hearon BA, RK MH, Calkins AW, Pratt E, Murray HW, Safren SA, Pollack MH. A randomized, controlled trial of the efficacy of an interoceptive exposure-based CBT for treatment-refractory outpatients with opioid dependence. J Psychoactive Drugs. 2014;46(5):402–11.CrossRefPubMed
57.
Darker C, Sweeney B, El Hassan H, Kelly A, O’Connor S, Smyth B, Barry J. Non-attendance at counselling therapy in cocaine-using methadone-maintained patients: lessons learnt from an abandoned randomised controlled trial. Ir J Med Sci. 2012;181(4):483–9.CrossRefPubMed
58.
Orford J. Asking the right questions in the right way: the need for a shift in research on psychological treatments for addiction. Addiction. 2008;103(6):875–85.CrossRefPubMed
59.
Schwartz RP, Kelly SM, O’Grady KE, Gandhi D, Jaffe JH. Randomized trial of standard methadone treatment compared to initiating methadone without counseling: 12-month findings. Addiction. 2012;107:943–52.CrossRefPubMedPubMedCentral
60.
McKay JR. Making the hard work of recovery more attractive for those with substance use disorders. Addiction. 2017;112(5):751–7.CrossRefPubMed
61.
Manuel JK, Hagedorn HJ, Finney JW. Implementing evidence-based psychosocial treatment in specialty substance use disorder care. Psychol Addict Behav. 2011;25(2):225–37.CrossRefPubMedPubMedCentral
62.
Weaver T, Metrebian N, Hellier J, Pilling S, Charles V, Little N, Poovendran D, Mitcheson L, Ryan F, Bowden-Jones O, et al. Use of contingency management incentives to improve completion of hepatitis B vaccination in people undergoing treatment for heroin dependence: a cluster randomised trial. Lancet. 2015;384(9938):153-63.
63.
Lussier JP, Heil SH, Mongeon JA, Badger GJ, Higgins ST. A meta-analysis of voucher-based reinforcement therapy for substance use disorders. Addiction. 2006;101(2):192–203.CrossRefPubMed
Metadata
Title
A pilot feasibility randomised controlled trial of an adjunct brief social network intervention in opiate substitution treatment services
Authors
Ed Day
Alex Copello
Jennifer L. Seddon
Marilyn Christie
Deborah Bamber
Charlotte Powell
Carmel Bennett
Shabana Akhtar
Sanju George
Andrew Ball
Emma Frew
Ilias Goranitis
Nick Freemantle
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2018
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/s12888-018-1600-7

Other articles of this Issue 1/2018

BMC Psychiatry 1/2018 Go to the issue

Study protocol

B-positive: a randomized controlled trial of a multicomponent positive psychology intervention for euthymic patients with bipolar disorder - study protocol and intervention development

Research article

Cross-cultural generalizability of suicide first aid actions: an analysis of agreement across expert consensus studies from a range of countries and cultures

Research article

Genetic association of human Corticotropin-Releasing Hormone Receptor 1 (CRHR1) with Internet gaming addiction in Korean male adolescents

Research article

BEATVIC, a body-oriented resilience therapy using kickboxing exercises for people with a psychotic disorder: a feasibility study

Research article

Does Chinese calligraphy therapy reduce neuropsychiatric symptoms: a systematic review and meta-analysis

Research article

A systematic review and meta-analysis of epidemiology of depression in people living with HIV in east Africa